\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes SecurityUnder the Horizon Europe: Cluster 3 - Civil Security for Society programme, managed by the European Research Executive Agency, police authorities are not just passive recipients of research outcomes. Instead, they play an active and pivotal role as participants in EU projects.
In security research projects, law enforcement authorities collaborate closely with academia and industry to ensure that project outcomes effectively address capability gaps and operational needs.
In an interview, Lieutenant-Colonel Daniel Camara, who works at the French Gendarmerie’s Centre for Forensic Artificial Intelligence, gave 3 valuable tips on how law enforcement authorities can maximise the benefits of their participation in an EU research project:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The European Cybersecurity Competence Centre (ECCC) has opened a call for tenders to set up a European testing infrastructure for post-quantum cryptography (PQC). Open to applicants across the European Economic Area, the contract is worth EUR 25 million and covers IT services including development and support. The submission deadline is 20 Februa... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
